{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Complete response is normalization of abnormal blood counts, and disappearance of signs of morphological changes in the bone marrow. If the previously present cytogenetic abnormalities are absent then it is referred also as a cytogenetic complete remission.","groups":[{"id":"OG000","title":"Azacitidine and Darbopoietin and G-CSF"}],"paramType":"NUMBER","populationDescription":"There were a total of 3 patients accrued on this trial. All were eligible and evaluable for response and evaluable for toxicity, as per protocol.","reportingStatus":"POSTED","timeFrame":"Approximately 112 days","title":"Number of Participants With Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}